Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD

Next Previous
Search
Trial Profile

A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vorolanib (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions; First in man
  • Acronyms DAVIO; DAVIO 1
  • Sponsors EyePoint Pharmaceuticals

    • Most Recent Events

    • 01 Apr 2024 According to an EyePoint Pharmaceuticals media release, results from this trial were published in the Ophthalmology Science.
    • 01 Nov 2023 According to an EyePoint Pharmaceuticals media release, subgroup analyses were presented at the EURETINA Congress and the Retina Society Annual Meeting in October.
    • 30 Oct 2023 According to an EyePoint Pharmaceuticals media release, company will present interim masked safety data through October 1, 2023 in 173 patients rom the ongoing Phase 2 PAVIA, DAVIO 2 and DAVIO 1 trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top